Prevail Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Prevail Therapeutics Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PRVL

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Prevail Therapeutics Inc. (NASDAQ: PRVL) to Eli Lilly and Company is fair to Prevail shareholders. Under the terms of the merger agreement, Prevail shareholders will receive $22.50 per share in cash plus one non-tradable contingent value right worth up to $4.00 per share in cash.

Halper Sadeh encourages Prevail shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

The investigation concerns whether Prevail and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Prevail shareholders; (2) determine whether Eli Lilly is underpaying for Prevail; and (3) disclose all material information necessary for Prevail shareholders to adequately assess and value the merger consideration. On behalf of Prevail shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Prevail shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.